Sermorelin vs Tesamorelin: What Is the Difference?

Same receptor, different stability. Sermorelin and tesamorelin are both versions of growth hormone-releasing hormone, the hypothalamic peptide that instructs the pituitary to release growth hormone 1. They bind the same receptor and set off the same downstream event. What separates them is chemistry at one end of the molecule: sermorelin is the plain active fragment, which an enzyme in blood begins dismantling within minutes, while tesamorelin carries an attached chemical group that blocks that reaction. That difference in stability is the reason the two have such different research and regulatory histories, and it is the only difference between them that is genuinely established.

Do they act on the same receptor?

Yes. Both bind the growth hormone-releasing hormone receptor on pituitary cells, and both are recognised by it because both are built from the same natural sequence. This is the point that most comparisons of the pair get right and then immediately abandon.

The natural hormone was characterised in 1982, and the circumstances are worth knowing because they explain the shape of everything that followed. Hypothalamic hormones exist in vanishingly small quantities, and for years nobody could isolate enough of this one to sequence it. The breakthrough came from pancreatic tumours that were producing the hormone in large amounts and causing acromegaly as a side effect; material from one of those tumours gave researchers the quantity they needed 1. The sequence turned out to be 44 amino acids long, and work that followed established that the first 29 of those residues carry essentially the full activity of the whole molecule.

That 1-29 fragment is sermorelin. It is not a designed analogue in any meaningful sense; it is the natural hormone with the biologically redundant tail left off. Once synthesis became practical, that fragment moved into human studies quickly, including early work in children with growth failure showing that a releasing factor given from outside could raise growth rate through the body's own pituitary 2. Tesamorelin starts from the full 44-residue sequence instead, and adds something to it.

What does the modification actually buy?

Time in circulation, and nothing else. Tesamorelin carries a small fatty acid group attached to the exposed end of the peptide, and its only job is to obstruct the enzyme that would otherwise cut the molecule apart.

The enzyme in question, dipeptidyl peptidase-4, is abundant in blood and removes two amino acids from the free end of susceptible peptides. It is a fast reaction. Unprotected releasing hormone, and therefore sermorelin, is degraded on a timescale of minutes, which is not a defect of the molecule so much as its natural design: a hormone that travels a short distance from the hypothalamus to the pituitary and then needs to stop signalling has no reason to be durable. It becomes a defect only when the molecule is asked to survive a journey through the whole circulation.

Attaching a bulky hydrophobic group at that end obstructs the enzyme's access. This is a well-established strategy across peptide drug development rather than anything specific to this compound, and its consequences are well understood. It gives a longer measurable presence and a flatter concentration curve. What it explicitly does not give is a different mechanism, a different receptor, or a different downstream signal. Whatever the modified molecule achieves, it achieves through the same receptor as the unmodified one.

Which one has more human trial data?

Tesamorelin, by a wide margin, and almost all of it comes from one specific patient population. The compound was developed for a condition called HIV-associated lipodystrophy, in which certain antiretroviral regimens are followed by an accumulation of visceral fat — the fat around the abdominal organs rather than under the skin.

That development programme produced the kind of evidence most compounds discussed on this site do not have. A randomised placebo-controlled trial reported reduced visceral adipose tissue in treated patients relative to placebo, measured by computed tomography rather than by tape measure or self-report 3. Two multicentre phase 3 trials followed, and their pooled analysis reported a visceral fat reduction of roughly 15 to 18 per cent against placebo, along with safety data from an extension period 4. A later randomised trial examined liver fat as well as visceral fat in the same population 5. Registered trials, placebo controls, imaging endpoints, pre-specified analyses: this is an ordinary drug development programme, and it is what a serious evidence base looks like.

Sermorelin's human record is older, smaller and differently shaped. It was studied largely as a diagnostic and therapeutic tool in growth hormone deficiency, particularly in children, where the underlying question was whether stimulating the pituitary from outside could substitute for a failing hypothalamic signal 2. That work is real, and it is also decades old, conducted before much of the trial reporting infrastructure that governs modern studies existed. It does not amount to a modern outcome-trial programme, and nothing published since has supplied one.

Is either one an approved medicine?

Tesamorelin is; sermorelin, in most jurisdictions, currently is not. Tesamorelin holds a marketing authorisation for the reduction of excess abdominal fat in patients with HIV-associated lipodystrophy, granted on the strength of the trials described above. Sermorelin was marketed as an approved product in the past and was subsequently withdrawn by its manufacturer; it is not generally available as a licensed medicine today.

It is important to state what that status is and is not. An approval is a regulatory finding that a specific product, made to a specific manufacturing standard, showed an acceptable balance of benefit and risk for one named indication in one studied population. It is a fact about a dossier. It is not a general endorsement of the molecule, it does not extend to other populations or purposes, and it is emphatically not a route by which anyone reading a web page obtains anything. Material sold for laboratory research under either name is not the approved product, was not manufactured to that standard, and inherits none of that regulatory status.

The withdrawal of a product also deserves care, because it is routinely misread in both directions. A product leaving the market is not automatically evidence that it failed or harmed anyone; commercial decisions, small patient populations and the economics of maintaining a licence all remove products that nothing was ever wrong with. Equally, a withdrawal is not nothing. The accurate reading is that a compound no longer on the market has stopped accumulating the regulatory oversight, adverse event reporting and manufacturing scrutiny that a marketed medicine attracts.

• An approval covers one indication, one population and one manufactured product — never a molecule in general.
• Research-grade material carries no regulatory status regardless of what the same molecule holds elsewhere.
• Withdrawal from a market is frequently commercial and is not by itself a safety finding.
• Growth hormone-releasing hormone analogues as a class are prohibited in competitive sport under World Anti-Doping Agency rules.
• Neither compound has published outcome trials for the general purposes they are informally discussed for.

What can this comparison not tell you?

It cannot tell you that one works better than the other, because no study has ever compared them. Everything above is assembled from two separate literatures written decades apart for different purposes in different populations, and placing two such literatures in a table does not turn them into a trial.

The population problem is the sharpest limitation. Tesamorelin's evidence was generated in patients with a specific metabolic complication of a specific antiretroviral treatment history. Visceral fat accumulation in that setting has particular causes, and a compound that reduces it there has been shown to reduce it there. Whether the same effect appears in people without that condition is not something the trials examined, and results do not travel from one population to another simply because a body part is shared. This is the most common inferential error made about tesamorelin, and the trials themselves are scrupulous about it even when the summaries of them are not 45.

The second limitation is the stability question itself. It is tempting to assume that the longer-lasting molecule must be the better one, since it was the one taken through full development. But the developer chose the stable molecule because a compound surviving minutes in blood is difficult to build a product around, not because anyone demonstrated that a sustained signal outperforms a pulsatile one at the receptor. That comparison has not been run. Growth hormone release is naturally pulsatile, and whether flattening that pattern is an improvement or a compromise remains genuinely open 1.

So the short answer. These are the same key cut two ways: one plain, one armoured. The armouring bought enough durability to make a development programme feasible, and that programme produced real randomised evidence in one narrow patient group. Sermorelin has the older, thinner record and no current licence. Neither of those facts is a statement about which molecule is better at the receptor, because nobody has asked that question in a study designed to answer it.